Table 1.

Effects of indicated treatments on body weight, visceral fat mass, liver weight, plasma glucose, and food intake in mice

	Control	Standard metformin	Low-dose metformin	Very low-dose metformin	Low-dose metformin + resveratrol-HMB	Very low-dose metformin + resveratrol-HMB
Body weight (g) (start)	45.0 ± 0.6a	45.2 ± 0.8a	45.1 ± 0.6a	44.4 ± 0.9a	45.6 ± 1.0a	46.7 ± 0.6a
Body weight (g) (end)	46.8 ± 0.7a	48.6 ± 0.6a	48.2 ± 0.4a	46.3 ± 1.1a	48.3 ± 1.0a	47.9 ± 1.0a
Plasma glucose (mg/dL)	481.3 ± 25.0a	460.1 ± 24.7a	482.3 ± 15.4a	503.0 ± 17.0a	433.7 ± 51.6a	529.1 ± 18.6a
Visceral fat (g)	4.5 ± 0.18a	4.3 ± 0.29a	4.6 ± 0.14a	4.4 ± 0.13a	3.8 ± 0.19b	3.6 ± 0.23b
Liver (g)	2.78 ± 0.16a	2.76 ± 0.09a	2.65 ± 0.09a	2.68 ± 0.12a	2.35 ± 0.13b	2.41 ± 0.08b

Notes:db/db mice were fed the indicated diets for 2 weeks. Data are expressed as the mean ± standard error of the mean (n = 10). Values with the same letter superscripts in each row are not significantly different from each other; values with nonmatching letter superscripts in each row indicate significant differences between groups (P < 0.03).

Abbreviation: HMB, hydroxymethylbutyrate.